Pediatric superior vena cava syndrome: An evidence-based systematic review of the literature
Corresponding Author
Fadi Nossair
Division of Oncology, CHOC Children's, Orange, California
Division of Hematology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Correspondence
Fadi Nossair, CHOC Children's, 1201 W La Veta Ave, Orange, CA 92868.
Email: [email protected]
Search for more papers by this authorPeter Schoettler
Department of Pediatrics, University of California–Irvine, Irvine, California
Department of Pediatrics, CHOC Children's, Orange, California
Search for more papers by this authorJoanne Starr
Division of Cardiothoracic Surgery, CHOC Children's, Orange, California
Search for more papers by this authorAnthony K. C. Chan
Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorIvan Kirov
Division of Oncology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Search for more papers by this authorBosco Paes
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorArash Mahajerin
Division of Hematology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Search for more papers by this authorCorresponding Author
Fadi Nossair
Division of Oncology, CHOC Children's, Orange, California
Division of Hematology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Correspondence
Fadi Nossair, CHOC Children's, 1201 W La Veta Ave, Orange, CA 92868.
Email: [email protected]
Search for more papers by this authorPeter Schoettler
Department of Pediatrics, University of California–Irvine, Irvine, California
Department of Pediatrics, CHOC Children's, Orange, California
Search for more papers by this authorJoanne Starr
Division of Cardiothoracic Surgery, CHOC Children's, Orange, California
Search for more papers by this authorAnthony K. C. Chan
Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorIvan Kirov
Division of Oncology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Search for more papers by this authorBosco Paes
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
Search for more papers by this authorArash Mahajerin
Division of Hematology, CHOC Children's, Orange, California
Department of Pediatrics, University of California–Irvine, Irvine, California
Search for more papers by this authorAbstract
Superior vena cava syndrome (SVCS) results in vascular, respiratory, and neurologic compromise. A systematic search was conducted to determine the prevalence of pediatric SVCS subtypes and identify clinical characteristics/treatment strategies that may influence overall outcomes. Data from 101 case reports/case series (142 patients) were analyzed. Morbidity (30%), mortality (18%), and acute complications (55%) were assessed as outcomes. Thrombosis was present in 36%, with multi-modal anticoagulation showing improved outcome by >50% (P = 0.004). Infant age (P = 0.04), lack of collaterals (P = 0.007), acute complications (P = 0.005), and clinical presentation may have prognostic utility that could influence clinical decisions and surveillance practices in pediatric SVCS.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Supporting Information
| Filename | Description |
|---|---|
| pbc27225-sup-0001-TableS1.docx65 KB | Supplemental Table S1: Symptoms & signs used for the cumulative score |
| pbc27225-sup-0002-TableS2.docx113.1 KB | Supplemental Table S2: Radiological modalities and their findings (n = 142) |
| pbc27225-sup-0003-TableS3.docx103.3 KB | Supplemental Table S3: Acute complications as secondary outcome in relation to multiple clinical factors |
| pbc27225-sup-0004-TableS4.docx101 KB | Supplemental Table S4: SVCS recurrence as secondary outcome in relation to multiple clinical factors |
| pbc27225-sup-0005-TableS5.docx162.1 KB | Supplemental Table S5: Cohort or case-control studies involving children with SVCS |
| pbc27225-sup-0006-SuppMat.docx160.4 KB | Supplemental Material S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Jain R, Bansal D, Marwaha RK, Singhi S. Superior mediastinal syndrome: emergency management. Indian J Pediatr. 2013; 80: 55–59.
- 2Swaniker F, Fonkalsrud EW. Superior and inferior vena caval occlusion in infants receiving total parenteral nutrition. Am Surg. 1995; 61: 877–881.
- 3Kazanci SY, McElhinney DB, Thiagarajan R, et al. Obstruction of the superior vena cava after neonatal extracorporeal membrane oxygenation: association with chylothorax and outcome of transcatheter treatment. Pediatr Crit Care Med. 2013; 14: 37–43.
- 4Tzifa A, Marshall AC, McElhinney DB, Lock JE, Geggel RL. Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population: a 22-year experience. J Am Coll Cardiol. 2007; 49: 1003–1009.
- 5Zreik H, Bengur AR, Meliones JN, Hansell D, Li JS. Superior vena cava obstruction after extracorporeal membrane oxygenation. J Pediatr. 1995; 127: 314–316.
- 6Ing FF, Mullins CE, Grifka RG, et al. Stent dilation of superior vena cava and innominate vein obstructions permits transvenous pacing lead implantation. Pacing Clin Electrophysiol. 1998; 21: 1517–1530.
- 7Hallgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol. 2012; 8: 23–34.
- 8Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159–174.
- 9Rizvi AZ, Kalra M, Bjarnason H, Bower TC, Schleck C, Gloviczki P. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008; 47: 372–380.
- 10Zartner P, Toussaint-Goetz N, Wiebe W, Schneider M. Vascular interventions in young patients undergoing transvenous pacemaker revision. Catheter Cardiovasc Interv. 2011; 78: 920–925.
- 11Aldoss O, Arain N, Menk J, Kochilas L, Gruenstein D. Endovascular stent provides more effective early relief of SVC obstruction compared to balloon angioplasty. Catheter Cardiovasc Interv. 2014; 83: E272–276.
- 12Tilak TV, Raina V, Kumar L, et al. Superior vena cava syndrome and poor performance status at presentation affect survival in mediastinal T-lymphoblastic lymphoma–a single institute experience from India. Ann Hematol. 2013; 92: 917–923.
- 13Dosios T, Theakos N, Chatziantoniou C. Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Chest. 2005; 128: 1551–1556.
- 14Bagheri R, Rahim M, Rezaeetalab F, Akbari H, Shojaian R. Malignant superior vena cava syndrome: is this a medical emergency. Ann Thoracic Cardiovas surg. 2009; 15: 89–92.
- 15Chan RC, Chan YC, Cheng SW. Mid- and long-term follow-up experience in patients with malignant superior vena cava obstruction. Interact Cardiovasc Thorac Surg. 2013; 16: 455–458.
- 16Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels. AJR Am J Roentgenol. 1993; 161: 539–542.
- 17Tayade BO, Salvi SS, Agarwal IR. Study of superior vena cava syndrome–aetiopathology, diagnosis and management. J Assoc Physicians India. 1994; 42: 609–611.
- 18Arya LS, Narain S, Tomar S, Thavaraj V, Dawar R, Bhargawa M. Superior vena cava syndrome. Indian J Pediatr. 2002; 69: 293–297.
- 19Aldoss O, Arain NI, Vinocur JM, et al. Frequency of superior vena cava obstruction in pediatric heart transplant recipients and its relation to previous superior cavopulmonary anastomosis. Am J Cardiol. 2013; 112: 286–291.
